http://orcid.org/0000-0002-6305-8176
References
- Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000;121:458–465.
- Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002;16:438–440.
- Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmoly 2004;137:615–624.
- Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf 2002;25:233–250.
- Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina (Philadelphia, PA) 2010;30:260–266.
- Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1–11.
- Liu CS, Leonard TJ, Brown NA. The lens opacities case-control study. Arch Ophthalmol 1991;109:1635–1636.
- Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Investigat Ophthalmol Visual Sci 1996;37:613–618.
- Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563–7568.
- Margalit E, Kugler LJ, Brumm MV, et al. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci 2006;47:2093–2099.
- Komarowska I, Heilweil G, Rosenfeld PJ, et al. Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits. Retina (Philadelphia, PA) 2009;29:98–105.
- Faghihi H, Yahyapour H, Mahmoudzadeh R, et al. Comparison of intravitreal bevacizumab and intravitreal diclofenac in the treatment of diabetic macular edema: a 6-month follow-up. Med Hypothesis Discov Innov Ophthalmol 2017;6:67–75.
- Tsilimbaris MK, Tsika C, Kymionis GD. Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery. Ther Clin Risk Manag 2016;12:177–182.
- Soheilian M, Karimi S, Ramezani A, et al. Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol 2015;35:421–428.
- Baranano DE, Kim SJ, Edelhauser HF, et al. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol 2009;93:1387–1390.
- Soheilian M, Karimi S, Ramezani A, et al. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina (Philadelphia, PA) 2010 ;30:509–515.
- Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006;141:629–637.
- Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533–1538.
- Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986;31:102–110.
- Creighton MO, Sanwal M, Stewart-DeHaan PJ, et al. Modeling cortical cataractogenesis. V. Steroid cataracts induced by solumedrol partially prevented by vitamin E in vitro. Exp Eye Res 1983;37:65–76.
- Jobling AI, Augusteyn RC. Is there a glucocorticoid receptor in the bovine lens?. Exp Eye Res 2001;72:687–694.
- Dickerson JE Jr, Dotzel E, Clark AF. Steroid-induced cataract: new perspective from in vitro and lens culture studies. Exp Eye Res 1997;65:507–516.
- Wenk EJ, Hernandez MR, Weinstein BI, et al. Glucocorticoid receptor binding in bovine lens. Investigat Ophthalmol Visual Sci 1982;22:599–605.